XML 61 R48.htm IDEA: XBRL DOCUMENT v3.22.4
SEGMENT INFORMATION (Tables)
12 Months Ended
Dec. 31, 2022
Segment Reporting [Abstract]  
Schedule of segment revenues and profit
Segment revenues and profits for the years 2022, 2021 and 2020 were as follows:
(in millions)202220212020
Revenues:  
Salix$2,090 $2,074 $1,904 
International988 1,166 1,181 
Solta Medical300 308 253 
Diversified Products978 1,121 1,274 
Bausch + Lomb3,768 3,765 3,415 
Total revenues$8,124 $8,434 $8,027 
Segment profit:   
Salix$1,489 $1,493 $1,338 
International324 403 386 
Solta Medical135 167 131 
Diversified Products612 722 814 
Bausch + Lomb874 958 909 
Total3,434 3,743 3,578 
Corporate(828)(792)(619)
Amortization of intangible assets(1,215)(1,375)(1,645)
Goodwill impairments(824)(469)— 
Asset impairments, including loss on assets held for sale(15)(234)(114)
Restructuring, integration, separation and IPO costs(63)(50)(22)
Other expense, net(35)(373)(502)
Operating income454 450 676 
Interest income14 13 
Interest expense(1,464)(1,426)(1,534)
Gain (loss) on extinguishment of debt875 (62)(59)
Foreign exchange and other(8)(30)
Loss before income taxes$(129)$(1,024)$(934)
Schedule of capital expenditures, depreciation and amortization by segment
Capital expenditures by segment for the years 2022, 2021 and 2020 were as follows:
(in millions)202220212020
Capital expenditures:   
Salix$$$
International21 22 29 
Solta Medical
Diversified Products— — 
Bausch + Lomb178 201 253 
206 227 289 
Corporate14 42 13 
Total capital expenditures$220 $269 $302 
Schedule of revenues by segment and by product category Revenues by segment and product category were as follows:
SalixInternationalSolta MedicalDiversified ProductsBausch + LombTotal
(in millions)For the year ended December 31, 2022
Pharmaceuticals$2,090 $279 $— $826 $481 $3,676 
Devices— — 300 — 1,572 1,872 
OTC— 151 — 1,453 1,611 
Branded and Other Generics — 527 — 120 240 887 
Other revenues— 31 — 25 22 78 
$2,090 $988 $300 $978 $3,768 $8,124 
SalixInternationalSolta MedicalDiversified ProductsBausch + LombTotal
For the year ended December 31, 2021
Pharmaceuticals$2,066 $259 $— $924 $514 $3,763 
Devices— — 308 — 1,595 1,903 
OTC— 136 — 1,389 1,532 
Branded and Other Generics — 738 — 167 239 1,144 
Other revenues33 — 23 28 92 
$2,074 $1,166 $308 $1,121 $3,765 $8,434 
SalixInternationalSolta MedicalDiversified ProductsBausch + LombTotal
For the year ended December 31, 2020
Pharmaceuticals$1,899 $255 $— $1,020 $506 $3,680 
Devices— — 253 — 1,313 1,566 
OTC— 112 — 1,311 1,430 
Branded and Other Generics — 775 — 219 254 1,248 
Other revenues39 — 28 31 103 
$1,904 $1,181 $253 $1,274 $3,415 $8,027 
Schedule of revenues by geographic region
Revenues are attributed to a geographic region based on the location of the customer for the years 2022, 2021 and 2020 were as follows:
(in millions)202220212020
U.S. and Puerto Rico$4,836 $4,887 $4,791 
China413 490 341 
Canada351 343 331 
Poland278 280 238 
Mexico276 256 225 
Japan200 230 226 
France203 208 179 
Russia181 160 137 
Germany147 154 144 
United Kingdom115 116 86 
Spain84 88 78 
South Korea77 76 68 
Italy76 80 71 
Other887 1,066 1,112 
$8,124 $8,434 $8,027 
Schedule of long-lived assets by geographic region
Long-lived assets consisting of property, plant and equipment, net of accumulated depreciation, are attributed to geographic regions based on their physical location as of December 31, 2022 and 2021 were as follows:
(in millions)20222021
U.S. and Puerto Rico$725 $743 
Ireland363 336 
Canada126 123 
Germany89 87 
Poland65 75 
Mexico46 45 
France44 39 
China26 30 
Serbia23 25 
Italy 20 21 
Other 73 74 
$1,600 $1,598 
Schedule of external customers that accounted for 10% or more of total revenues
Customers that accounted for 10% or more of total revenues were as follows:
202220212020
AmerisourceBergen Corporation18%18%17%
McKesson Corporation15%16%17%
Cardinal Health, Inc.13%12%13%